Crude extract of Rheum palmatum inhibits migration and invasion of U-2 OS human osteosarcoma cells by suppression of matrix metalloproteinase-2 and -9

BioMedicine (Netherlands)

Volumn 3, Issue 3, 2013, Pages 120-129

  Hsu, Shu Chun ^a   Lin, Ju Hwa ^a   Weng, Shu Wen ^a,b   Chueh, Fu Shin ^c   Yu, Chien Chih ^a   Lu, Kung Wen ^a   Wood, W Gibson ^d   Chung, Jing Gung ^a,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG HOSPITAL   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Crude extract of Rheum palmatum; Invasion; Migration; U 2 OS human osteosarcoma cells

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RHUBARB EXTRACT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INVASION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ISOLATION; ENZYME INDUCTION; ENZYME REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOSARCOMA; OSTEOSARCOMA CELL; PHYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHUBARB; UPREGULATION;

EID: 84881357953     PISSN: 22118020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomed.2013.04.008     Document Type: Article

References (51)

1. Sangle N.A., Layfield L.J. Telangiectatic osteosarcoma. Arch Pathol Lab Med 2012, 136:572-576.
2. Huh W.W., Holsinger F.C., Levy A., Palla F.S., Anderson P.M. Osteosarcoma of the jaw in children and young adults. Head Neck 2012, 34:981-984.
3. Kaste S.C. Imaging pediatric bone sarcomas. Radiol Clin North Am 2011, 49:749-765.
4. Mirabello L., Troisi R.J., Savage S.A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009, 115:1531-1543.
5. Ward W.G., Mikaelian K., Dorey F., Mirra J.M., Sassoon A., Holmes E.C., et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 1994, 12:1849-1858.
6. Ishikawa M., Kondo H., Onuma M., Shibuya H., Sato T. Osteoblastic osteosarcoma in a rabbit. Comp Med 2012, 62:124-126.
7. Mohseny A.B., Machado I., Cai Y., Schaefer K.L., Serra M., Hogendoorn P.C., et al. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest 2011, 91:1195-1205.
8. Marina N., Gebhardt M., Teot L., Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004, 9:422-441.
9. Zhao G., Cai C., Yang T., Qiu X., Liao B., Li W., et al. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One 2013, 8. e53906.
10. Ng L., Poon R.T., Pang R. Biomarkers for predicting future metastasis of human gastrointestinal tumors. Cell Mol Life Sci 2013, 10.1007/s00018-013-1266-8.
11. Ren T.T., Guo W., Peng C.L., Lu X.C., Yang Y. Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway. Cancer Biol Ther 2010, 10:251-257.
12. Leow P.C., Tian Q., Ong Z.Y., Yang Z., Ee P.L. Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells. Invest New Drugs 2010, 28:766-782.
13. Fossey S.L., Bear M.D., Kisseberth W.C., Pennell M., London C.A. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer 2011, 11:125.
14. Berge G., Pettersen S., Grotterod I., Bettum I.J., Boye K., Maelandsmo G.M. Osteopontin - an important downstream effector of S100A4-mediated invasion and metastasis. Int J Cancer 2011, 129:780-790.
15. Korpi J.T., Hagstrom J., Lehtonen N., Parkkinen J., Sorsa T., Salo T., et al. Expression of matrix metalloproteinases-2, -8, -13,-26, and tissue inhibitors of metalloproteinase-1 in human osteosarcoma. Surg Oncol 2011, 20:e18-e22.
16. Lo T.C., Nian H.C., Chiu K.H., Wang A.Y., Wu B.Z. Rapid and efficient purification of chrysophanol in Rheum palmatum LINN by supercritical fluid extraction coupled with preparative liquid chromatography in tandem. J Chromatogr B Analyt Technol Biomed Life Sci 2012, 893-894:101-106.
17. Zheng C.D., Duan Y.Q., Gao J.M., Ruan Z.G. Screening for anti-lipase properties of 37 traditional Chinese medicinal herbs. J Chin Med Assoc 2010, 73:319-324.
18. Su X., Hu L., Kong L., Lei X., Zou H. Affinity chromatography with immobilized DNA stationary phase for biological fingerprinting analysis of traditional Chinese medicines. J Chromatogr A 2007, 1154:132-137.
19. Poon T.Y., Ong K.L., Cheung B.M. Review of the effects of the traditional Chinese medicine Rehmannia Six Formula on diabetes mellitus and its complications. J Diabetes 2011, 3:184-200.
20. Yokozawa T., Kang K.S., Park C.H., Noh J.S., Yamabe N., Shibahara N., et al. Bioactive constituents of Corni Fructus: the therapeutic use of morroniside, loganin, and 7-O-galloyl-D-sedoheptulose as renoprotective agents in type 2 diabetes. Drug Discov Ther 2010, 4:223-234.
21. Chen C.C., Hsu C.Y., Chen C.Y., Liu H.K. Fructus Corni suppresses hepatic gluconeogenesis related gene transcription, enhances glucose responsiveness of pancreatic beta-cells, and prevents toxin induced beta-cell death. J Ethnopharmacol 2008, 117:483-490.
22. Liu H., Xu H., Shen C., Wu C. Effect of the best compatibility of components in Corni Fructus on WT1 expression in glomerular podocytes of type 2 diabetic rats with early nephropathy. Am J Chin Med 2012, 40:537-549.
23. Park C.H., Tanaka T., Kim H.Y., Park J.C., Yokozawa T. Protective effects of Corni Fructus against advanced glycation endproducts and radical scavenging. Evid Based Complement Alternat Med 2012, 2012. 418953.
24. Roh C., Jung U. Screening of crude plant extracts with anti-obesity activity. Int J Mol Sci 2012, 13:1710-1719.
25. Park C.H., Noh J.S., Tanaka T., Uebaba K., Cho E.J., Yokozawa T. The effects of Corni Fructus extract and its fractions against alpha-glucosidase inhibitory activities invitro and sucrose tolerance in normal rats. Am J Chin Med 2011, 39:367-380.
26. Hwang J.H., Kim J.D. Inhibitory effects of Corni Fructus extract on angiogenesis and adipogenesis. Korean J Physiol Pharmacol 2011, 15:43-51.
27. Chiu Y.J., Hour M.J., Lu C.C., Chung J.G., Kuo S.C., Huang W.W., et al. Novel quinazoline HMJ-30 induces U-2 OS human osteogenic sarcoma cell apoptosis through induction of oxidative stress and up-regulation of ATM/p53 signaling pathway. J Orthop Res 2011, 29:1448-1456.
28. Huang W.W., Chiu Y.J., Fan M.J., Lu H.F., Yeh H.F., Li K.H., et al. Kaempferol induced apoptosis via endoplasmic reticulum stress and mitochondria-dependent pathway in human osteosarcoma U-2 OS cells. Mol Nutr Food Res 2010, 54:1585-1595.
29. Chueh F.S., Chen Y.Y., Huang A.C., Ho H.C., Liao C.L., Yang J.S., et al. Bufalin-inhibited migration and invasion in human osteosarcoma U-2 OS cells is carried out by suppression of the matrix metalloproteinase-2, ERK, and JNK signaling pathways. Environ Toxicol 2011, 10.1002/tox.20769.
30. Chen K.T., Hour M.J., Tsai S.C., Chung J.G., Kuo S.C., Lu C.C., et al. The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor. Int J Oncol 2011, 39:611-619.
31. Liu A., Chen H., Wei W., Ye S., Liao W., Gong J., et al. Antiproliferative and antimetastatic effects of emodin on human pancreatic cancer. Oncol Rep 2011, 26:81-89.
32. Wang C.-G., Yang J.-Q., Liu B.-Z., Jin D.-T., Wang C., Zhong L., et al. Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines invitro and invivo. Eur J Pharmacol 2010, 627:33-41.
33. Kang S.C., Lee C.M., Choung E.S., Bak J.P., Bae J.J., Yoo H.S., et al. Anti-proliferative effects of estrogen receptor-modulating compounds isolated from Rheum palmatum. Arch Pharm Res 2008, 31:722-726.
34. Toth M., Sohail A., Fridman R. Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. Methods Mol Biol 2012, 878:121-135.
35. Bianchi-Smiraglia A., Paesante S., Bakin A.V. Integrin beta5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene 2012, 10.1038/onc.2012.320.
36. Shen J., Xu L., Owonikoko T.K., Sun S.Y., Khuri F.R., Curran W.J., et al. NNK promotes migration and invasion of lung cancer cells through activation of c-Src/PKCiota/FAK loop. Cancer Lett 2012, 318:106-113.
37. Chien Y.C., Sheu M.J., Wu C.H., Lin W.H., Chen Y.Y., Cheng P.L., et al. A Chinese herbal formula "Gan-Lu-Yin" suppresses vascular smooth muscle cell migration by inhibiting matrix metalloproteinase-2/9 through the PI3K/AKT and ERK signaling pathways. BMC Complement Altern Med 2012, 12:137.
38. Wu M.H., Lo J.F., Kuo C.H., Lin J.A., Lin Y.M., Chen L.M., et al. Endothelin-1 promotes MMP-13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/mTOR pathways. J Cell Physiol 2012, 227:3016-3026.
39. Hwang Y.P., Yun H.J., Choi J.H., Han E.H., Kim H.G., Song G.Y., et al. Suppression of EGF-induced tumor cell migration and matrix metalloproteinase-9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling. Mol Nutr Food Res 2011, 55:594-605.
40. Nowicki T.S., Zhao H., Darzynkiewicz Z., Moscatello A., Shin E., Schantz S., et al. Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. Cell Cycle 2011, 10:100-107.
41. Ranson M., Andronicos N.M. Plasminogen binding and cancer: promises and pitfalls. Front Biosci 2003, 8:s294-s304.
42. Blasi F., Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010, 584:1923-1930.
43. Lobov S., Ranson M. Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: implications for cellular proteolysis and adhesion in cancer. Cancer Lett 2011, 303:118-127.
44. Struckhoff A.P., Rana M.K., Worthylake R.A. RhoA can lead the way in tumor cell invasion and metastasis. Front Biosci 2011, 16:1915-1926.
45. Gou L., Wang W., Tong A., Yao Y., Zhou Y., Yi C., et al. Proteomic identification of RhoA as a potential biomarker for proliferation and metastasis in hepatocellular carcinoma. J Mol Med (Berl) 2011, 89:817-827.
46. Lawler K., Foran E., O'Sullivan G., Long A., Kenny D. Mobility and invasiveness of metastatic esophageal cancer are potentiated by shear stress in a ROCK- and Ras-dependent manner. Am J Physiol Cell Physiol 2006, 291:C668-C677.
47. Lee S.H., Jeong E.G., Nam S.W., Lee J.Y., Yoo N.J. Increased expression of Gab2, a scaffolding adaptor of the tyrosine kinase signalling, in gastric carcinomas. Pathology 2007, 39:326-329.
48. Zhang J., Anastasiadis P.Z., Liu Y., Thompson E.A., Fields A.P. Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway. J Biol Chem 2004, 279:22118-22123.
49. Huang B., Cao K., Li X., Guo S., Mao X., Wang Z., et al. The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma. J Exp Clin Cancer Res 2011, 30:88.
50. Bolos V., Gasent J.M., Lopez-Tarruella S., Grande E. The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther 2010, 3:83-97.
51. Arpaia E., Blaser H., Quintela-Fandino M., Duncan G., Leong H.S., Ablack A., et al. The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene 2012, 31:884-896.